Univ of Hyderabad scientists find evidence to make HPIP key target in cancer drug development

M Somasekhar Hyderabad | Updated on August 19, 2019 Published on August 19, 2019

Scientists from the University of Hyderabad (UoH) probing HPIP, a known ‘culprit gene’ in the development of cancers, have stumbled upon evidence that promises to turn it into a key target in developing potential drugs in future.

They have researched its protein structure and understood its key role in cell division. The over expression of HPIP Gene is responsible for the growth of cancerous tumours, they state.

In 2015, the same research group led by Bramanandam Manavathi, was the first to establish the role of HPIP Gene in the development of breast cancers, which is widely prevalent in India.

Subsequently, other research groups around the world have expanded its significance in other cancers of the liver, brain, stomach, etc, says Bramanandam.

The present work by the research team from the Department of Biochemistry, UoH, has been published in the Journal of Biological Chemistry (JBC).

The researchers feel that this fresh knowledge will help in the development of a candidate drug that could target the culprit gene and control or cure certain cancers in the near future.

“While HPIP’s role in cancer is well established, to consider it as a potential novel therapeutic target in cancer, its protein structure has to be unveiled, which might motivate us to identify the inhibitors for HPIP. We are partially successful in that direction, as we have found that it is a dimeric protein and its dimerisation is important for its functions (unpublished data),” Bramanandam explained.

Therefore, the focus of our research is to identify the small molecular synthetic inhibitors that block its dimerisation, its oncogenic functions and, thus, cure cancer, he said.

Cells & human body

The human body has several trillion cells. Each and every cell undergoes cell division and duplication of cells, to maintain our body system.

In normal cells, cell division proceeds through a series of precisely timed and carefully regulated stages of growth (G1 phase), DNA synthesis (S phase), preparatory phase for division (G2), chromosome segregation (M-mitosis), and division (cytokinesis) that produces two identical daughter cells.

A well-regulated mechanism controls the cell division. Uncontrollable cell division leads to cancer.

Studying the defect or role of proteins in each phase of the cell cycle is an emerging area in the field of cancer, to control cancer cell growth.

“Our main study focuses on the M phase, where chromosome separation and distribution to pre-daughter cell occurs, and cytokinesis, where cell division takes place to give rise to two daughter cells”, the UoH says.

“By lowering HPIP production using the viral transduction method, we discovered that there is a chromosome segregation defect with multiple spindle formation and chromosomal abnormalities, resulting in defective cytokinesis and delay in M phase transition.”

The UoH team has taken up further research.

Published on August 19, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.